Investigational thymic stromal lymphopoietin inhibitors for the treatment of asthma: a systematic review.
Rogliani PaolaGian Marco ManzettiFederica Roberta BettinMaria D'AuriaLuigino CalzettaPublished in: Expert opinion on investigational drugs (2024)
TSLP contributes to airway inflammation, making it a pivotal therapeutic target. Ecleralimab, an inhaled antibody fragment antigen binding, shows promising evidence in enhancing efficacy and reducing systemic adverse events. SAR443765, with its NANOBODY® formulation and bispecific inhibition of TSLP and IL-13, offers improved tissue penetration and efficacy. The mAB TQC2731 exhibits high in vitro bioactivity, and the strength of the mAb UPB-101 is to act against the TSLP receptor. Some studies include mild and moderate asthma patients, suggesting the potential for extending biological therapy to non-severe patients. This systematic review highlights the potential of TSLP inhibitors as valuable additions to asthma treatment, even in milder forms of the disease. Future research and cost-reduction efforts are needed to expanding access to these promising therapies.
Keyphrases
- systematic review
- end stage renal disease
- chronic obstructive pulmonary disease
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- lung function
- randomized controlled trial
- bone marrow
- allergic rhinitis
- stem cells
- combination therapy
- transcription factor
- quality improvement
- cell therapy
- study protocol
- monoclonal antibody
- meta analyses
- dna binding